BACKGROUND: Edoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics. Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure. OBJECTIVE: To assess the potential pharmacokinetic interactions of edoxaban and 6 cardiovascular drugs used in the management of AF and known P-gp substrates/inhibitors. METHODS: Drug-drug interaction studies with edoxaban and CV drugs with known P-gp substrate/inhibitor potential were conducted in healthy subjects. In 4 cro...
Purpose: Pharmacokinetic interactions exist between apixaban or rivaroxaban, and CYP3A4 and Pglycopr...
Purpose: Pharmacokinetic interactions exist between apixaban or rivaroxaban, and CYP3A4 and Pglycopr...
Objectives: Rivaroxaban is a known substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and the P-gl...
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagu...
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagu...
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagu...
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagu...
INTRODUCTION:Edoxaban is a novel factor Xa inhibitor. This study characterizes the population pharma...
INTRODUCTION:Edoxaban is a novel factor Xa inhibitor. This study characterizes the population pharma...
Warfarin is dependent on multiple hepatic enzymes for metabolism while apixaban is a substrate for P...
The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned by clinici...
Charles Frost,1 Yan Song,1 Zhigang Yu,2 Jessie Wang,3 Lois S Lee,4 Alan Schuster,5 Allyson Pollack,1...
The direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, are becomin...
Contains fulltext : 202664.pdf (Publisher’s version ) (Closed access)Warfarin is d...
INTRODUCTION: Non-vitamin K antagonist oral anticoagulants (NOACs) have been developed to prevent is...
Purpose: Pharmacokinetic interactions exist between apixaban or rivaroxaban, and CYP3A4 and Pglycopr...
Purpose: Pharmacokinetic interactions exist between apixaban or rivaroxaban, and CYP3A4 and Pglycopr...
Objectives: Rivaroxaban is a known substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and the P-gl...
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagu...
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagu...
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagu...
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagu...
INTRODUCTION:Edoxaban is a novel factor Xa inhibitor. This study characterizes the population pharma...
INTRODUCTION:Edoxaban is a novel factor Xa inhibitor. This study characterizes the population pharma...
Warfarin is dependent on multiple hepatic enzymes for metabolism while apixaban is a substrate for P...
The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned by clinici...
Charles Frost,1 Yan Song,1 Zhigang Yu,2 Jessie Wang,3 Lois S Lee,4 Alan Schuster,5 Allyson Pollack,1...
The direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, and edoxaban, are becomin...
Contains fulltext : 202664.pdf (Publisher’s version ) (Closed access)Warfarin is d...
INTRODUCTION: Non-vitamin K antagonist oral anticoagulants (NOACs) have been developed to prevent is...
Purpose: Pharmacokinetic interactions exist between apixaban or rivaroxaban, and CYP3A4 and Pglycopr...
Purpose: Pharmacokinetic interactions exist between apixaban or rivaroxaban, and CYP3A4 and Pglycopr...
Objectives: Rivaroxaban is a known substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and the P-gl...